Circumcision in hemophilia using low quantity of factor concentrates: experience from Dakar, Senegal.

Background: Circumcision in hemophiliacs is a delicate surgery because of bleeding risks that could be avoided by adequate substitution of coagulation factor. This practice is very challenging in countries where anti hemophilic treatment is inaccessible. The study aimed to evaluate a circumcision protocol in hemophilia A using low quantities of factor concentrates.

Methods: This prospective study included 26 hemophiliacs A who underwent circumcision in 2014. Medical treatment protocol using low quantity of factor concentrates was drafted by physicians of the Hemophilia Treatment Center and the surgical protocol by experienced surgeons. Assessment criteria were: number of hospitalization days, number of exposure days to factor concentrates, delay to healing and occurrence of bleeding events.

Results: Mean age was 9.6 years (1-30). Hemophiliacs patients were classified as severe ( = 8), moderate ( = 9) and mild form ( = 9). Mean number of exposure days to factor VIII concentrates was 6.9 days (5-12) in children and 10.75 days (7-16) in adults ( = 0.0049); mean number of hospitalization days was 3.68 days (2-10) in children and 13.5 days (13-15) in adults ( = 0.0000); delay to healing was 26.47 days (20-35) in children and 25.25 days (22-30) in adults ( = 0.697); five haemophiliacs (19.2%) presented bleeding events after the circumcision. The mean amount of FIII concentrates used per patient was 1743 IU (810-2340).

Conclusion: The study shows treatment protocol using low quantity of factor concentrates is efficient in hemophilia patients who underwent circumcision.